Troglitazone
August 24, 2000
NEW YORK, August 18 (Praxis Press). Troglitazone, a member of a new class of antidiabetic drugs, increases insulin sensitivity and promotes adipocyte differentiation. This drug may therefore be therapeutic in patients with lipoatrophic and lipodystrophic disorders. Arioglu and colleagues studied the effects of open-label troglitazone treatment in 20 patients with lipoatrophy and insulin resistance. After 6 months of treatment, fasting triglyceride levels decreased by 2.6 mmol/L (p = 0.019); free




